Journal
BIOSENSORS & BIOELECTRONICS
Volume 195, Issue -, Pages -Publisher
ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2021.113663
Keywords
Tuberculosis; Point-of-care; Microfluidics; Finger-driven; RPA
Categories
Funding
- Beijing Natural Science Foundation [7212204]
- NSFC [32071407, 61971294, 82060389, 62003023]
- Fundamental Research Funds for the Central Universities [JKF-YG-20-Z001]
- 111 Project [B13003]
- Special Research Funding on COVID-19 from Science and Technology Department of Sichuan Province [2020YFS0579, 2020YFS004-2]
- National Natural Science Foundation Regional Innovation and Development [U20A20394]
- 1.3.5 project for disciplines of excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University [2020HXFH015]
- Beijing Advanced Innovation Center for Biomedical Engineering at Beihang University
Ask authors/readers for more resources
A low-cost, portable finger-driven microfluidic chip was developed for rapid on-site detection of tuberculosis, showing unique advantages in avoiding risks of infection or environmental contamination and enabling multiplexed detection to differentiate different strains of Mycobacterium. In clinical trials, the platform demonstrated high specificity and sensitivity.
Tuberculosis (TB) remains the high-risk infectious pathogen that caused global pandemic and high mortality, particularly in the areas lack in health resources. Clinical TB screening and diagnosis are so far mainly conducted on limited types of commercial platforms, which are expensive and require skilled personnel. In this work, we introduced a low-cost and portable finger-driven microfluidic chip (named Fd-MC) based on recombinase polymerase amplification (RPA) for rapid on-site detection of TB. After injection of the pre-treated sample solution, the pre-packaged buffer was driven by the pressure generated by the finger-actuated operation to accomplish sequential processes of diagnosis in a fully isolated microchannel. An in-situ fluorescence strategy based on FAMprobe was implemented for on-chip results read-out though a hand-held UV lamp. Hence, the Fd-MC proved unique advantageous for avoiding the risk of infection or environmental contamination. In addition, the Fd-MC was designed for multiplexed detection, which is able to not only identify TB/non-TB infection, but also differentiate between human Mycobacterium tuberculosis and Mycobacterium bovis. The platform was verified in 37 clinical samples, statistically with 100% specificity and 95.2% sensitivity as compared to commercial real-time RPA. Overall, the proposed platform eliminates the need on external pumps and skilled personnel, holding promise to POC testing in the resource-limited area.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available